Company ProfileWe are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
|Recent Press Releases||More >>|
|03/06/17||Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)|
|77% Mean Triglyceride Reduction in Patients with FCS
Reductions in Pancreatitis Events and Abdominal Pain
Webcast to Discuss Results March 6, 2017 at 8:30 am ET
CARLSBAD, Calif. and CAMBRIDGE, Mass., March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that the pivotal Phase 3 APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronem... |
|02/28/17||Ionis' 2016 Financial Results Outperform Financial Guidance|
|Conference Call Webcast Tuesday, February 28, 11:30 a.m. ET at www.ionispharma.com
CARLSBAD, Calif., Feb. 28, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments. The Company also reported a GAAP loss from operations of $46.3 million.
"2016 was a year o... |
|02/16/17||Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx|
|- Ionis and Akcea to receive $75 million up-front payment
- Deal valued at more than $1 billion
CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today they have closed on their exclusive, worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx following clearance unde... |
|02/15/17||Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call|
|Webcast scheduled for Tuesday, February 28 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., Feb. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 28 at 11:30 a.m. Eastern Time to discuss its 2016 financial results and report on pipeline and business progress.
Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A ... |
For more information requests, please visit our Information Request page.
If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.
Data provided by Nasdaq. Minimum 15 minutes delayed.